These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 8621919)

  • 1. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
    Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S
    J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
    Ostrand-Rosenberg S; Baskar S; Patterson N; Clements VK
    Tissue Antigens; 1996 May; 47(5):414-21. PubMed ID: 8795142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
    La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
    J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rejection of mouse sarcoma cells after transfection of MHC class II genes.
    Ostrand-Rosenberg S; Thakur A; Clements V
    J Immunol; 1990 May; 144(10):4068-71. PubMed ID: 2332639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
    Moro M; Gasparri AM; Pagano S; Bellone M; Tornaghi P; Veglia F; Corti A; Casorati G; Dellabona P
    Cancer Res; 1999 Jun; 59(11):2650-6. PubMed ID: 10363988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
    Chen PW; Ananthaswamy HN
    J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
    Martin-Fontecha A; Cavallo F; Bellone M; Heltai S; Iezzi G; Tornaghi P; Nabavi N; Forni G; Dellabona P; Casorati G
    Eur J Immunol; 1996 Aug; 26(8):1851-9. PubMed ID: 8765031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.
    Matulonis U; Dosiou C; Freeman G; Lamont C; Mauch P; Nadler LM; Griffin JD
    J Immunol; 1996 Feb; 156(3):1126-31. PubMed ID: 8557988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costimulation provided by DNA immunization enhances antitumor immunity.
    Corr M; Tighe H; Lee D; Dudler J; Trieu M; Brinson DC; Carson DA
    J Immunol; 1997 Nov; 159(10):4999-5004. PubMed ID: 9366427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule.
    Ostrand-Rosenberg S; Roby CA; Clements VK
    J Immunol; 1991 Oct; 147(7):2419-22. PubMed ID: 1918972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
    Leong C; Marley J; Loh S; Robinson B; Garlepp M
    Cancer Gene Ther; 1996; 3(5):321-30. PubMed ID: 8894251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triptolide inhibits proinflammatory factor-induced over-expression of class II MHC and B7 molecules in renal tubular epithelial cells.
    Li H; Liu ZH; Dai CS; Liu D; Li LS
    Acta Pharmacol Sin; 2002 Sep; 23(9):775-81. PubMed ID: 12230943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrosarcoma cells expressing allogeneic MHC Class II antigens induce protective antitumor immunity.
    Leach DR; Callahan GN
    J Immunol; 1995 Jan; 154(2):738-43. PubMed ID: 7814880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
    Townsend SE; Su FW; Atherton JM; Allison JP
    Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
    Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
    Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules.
    Liu Y; Wang H; Zhao J; Ma J; Wei L; Wu S; Xie T; Shen F; Trojan J; Habib N; Anthony DD; Wu M; Guo Y
    Cancer Gene Ther; 2000 Mar; 7(3):456-65. PubMed ID: 10766352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
    Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
    Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.
    Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR
    Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation.
    Chaux P; Moutet M; Faivre J; Martin F; Martin M
    Lab Invest; 1996 May; 74(5):975-83. PubMed ID: 8642792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
    Yang G; Hellström KE; Hellström I; Chen L
    J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.